Yoon, A. J., Carvajal, R. D., Graboyes, E. M., Kaczmar, J. M., Albergotti, W. G., Kejner, A. E., Troob, S. H., Philipone, E., Anoma, J.-S., Armeson, K. E., Hill, E. G., Richardson, M. S., Woods, T. R., Chera, B. S., Nourollah-Zadeh, F., Lee, B. J., Pandruvada, S., Kourtidis, A., Kingsley, C., … Newman, J. G. (2025). Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1530262

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Ma, K. L., Mitchell, T. C., Dougher, M., Sharon, C. E., Tortorello, G. N., Elder, D. E., Morgan, E. E., Gimotty, P. A., Huang, A. C., Amaravadi, R. K., Schuchter, L. M., Flowers, A., Miura, J. T., Karakousis, G. C., & Xu, X. (2024). Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival. Clinical Cancer Research, 30(21), 4987–4994. https://doi.org/10.1158/1078-0432.ccr-23-3775

Huang, Y., Rauh-Hain, J. A., McCoy, T. H., Hou, J. Y., Hillyer, G., Ferris, J. S., Hershman, D., Wright, J. D., & Melamed, A. (2024). Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning. Gynecologic Oncology, 186, 9–16. https://doi.org/10.1016/j.ygyno.2024.03.016

Verheij, F. S., Omer, D. M., Lin, S. T., Yuval, J. B., Thompson, H. M., Kim, J. K., Valdivieso, S. C., Qin, L.-X., Wu, A. J., Saltz, L. B., & Garcia-Aguilar, J. (2024). Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial. International Journal of Radiation Oncology*Biology*Physics, 118(1), 115–123. https://doi.org/10.1016/j.ijrobp.2023.07.043

Vanguri, R. S., Fenn, K. M., Kearney, M. R., Wang, Q., Guo, H., Marks, D. K., Chin, C., Alcus, C. F., Thompson, J. B., Leu, C.-S., Hibshoosh, H., Kalinsky, K. M., Mathews, J. C., Nadeem, S., Hollmann, T. J., & Connolly, E. P. (2022). Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer. Clinical Breast Cancer, 22(6), 538–546. https://doi.org/10.1016/j.clbc.2022.04.002